



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

***iLite*[®] Infliximab NAb positive control**

REF: BM3136

For research use only. Not for use in diagnostic procedures.

DESCRIPTION

iLite[®] Infliximab NAb positive control is a polyclonal rabbit antibody with a neutralizing effect on Infliximab.

CONTENT

75 µL of *iLite*[®] Infliximab NAb positive control diluted in RPMI 1640 with 40% heat inactivated normal human serum (NHS).

RECEIPT AND STORAGE

Upon receipt confirm that adequate dry-ice is present, and the reagent is frozen. Immediately transfer to -80°C storage.

BACKGROUND

Tumor necrosis factor alpha (TNF-alpha) promotes inflammatory responses, which, in turn, contribute to the clinical problems associated with many inflammatory disorders, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and refractory asthma. These diseases are sometimes treated with TNF-alpha inhibitors, including infliximab, adalimumab, etanercept, certolizumab pegol or golimumab. Prolonged therapies with these TNF-alpha inhibitors may lead to development of neutralizing antibodies (NABs), which may counteract the TNF-alpha antagonist activity of the drugs.

APPLICATION

The *iLite*[®] Infliximab NAb positive control can be used as positive control for neutralizing antibodies against Infliximab.

Application Notes for the following assays are available:

- Determination of neutralizing antibodies against TNF-alpha blockers using *iLite*[®] TNF-alpha Assay Ready Cells (LABEL-DOC-0386)

RELATED PRODUCTS

REF	Product name
BM3044	<i>iLite</i> [®] TNF-alpha Assay Ready Cells
BM3133	<i>iLite</i> [®] TNF-alpha (16 ng/mL)
BM3134	<i>iLite</i> [®] Diluent B
BM3135	<i>iLite</i> [®] Reagent BLANK
BM3139	<i>iLite</i> [®] Diluent C
BM3159	<i>iLite</i> [®] Adalimumab NAb positive control
BM3177	<i>iLite</i> [®] Etanercept NAb positive control

REFERENCES

1. Lallemand C, Kavrochorianou A, Steenholdt C, Bendtzen K, Ainsworth MA, Meritet J-F, Blanchard B, Lebon P, Taylor P, Charles P, Alzabin S, Tovey MG. *Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists*. J Immunol Meth. 2011, 373: 229-239.

SYMBOLS ON LABEL

	Lot number		Temperature limitation
	Catalogue number		Biological risk
	Use by		Manufacturer

PRECAUTIONS

For research use only. This product is intended for professional laboratory research use only. The data and results originating from using the product, should not be used either in diagnostic procedures or in human therapeutic applications.

The product contains human/calf serum and if human serum is analysed it should be handled as if capable of transmitting infectious agents.

Residues of chemicals and preparations generally considered as biohazardous waste and should be inactivated prior to disposal by autoclaving or using bleach. All such materials should be disposed of in accordance with established safety procedures.

PROPRIETARY INFORMATION

In accepting delivery of *iLite*[®] Assay Ready Cells the recipient agrees not to sub-culture these cells, attempt to sub-culture them or to give them to a third party, and only to use them directly in assays. *iLite*[®] cell-based products are covered by patents which is the property of Svar Life Science AB and any attempt to reproduce the delivered *iLite*[®] Assay Ready Cells is an infringement of these patents.